

National Board of Examinations

Question Paper Name :	DrNB GYNAECOLOGICAL ONCOLOGY Paper3
Subject Name :	DrNB GYNAECOLOGICAL ONCOLOGY Paper3
Creation Date :	2025-01-19 21:59:39
Duration :	180
Total Marks :	100
Display Marks:	No
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DrNB GYNAECOLOGICAL ONCOLOGY Paper3

Group Number :	1
Group Id :	3271872811
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Break time :	0
Group Marks :	100

DrNB GYNAECOLOGICAL ONCOLOGY Paper3

Section Id :	3271872814
Section Number :	1
Section type :	Offline
Mandatory or Optional :	Mandatory
Number of Questions :	10
Number of Questions to be attempted :	10
Section Marks :	100
Maximum Instruction Time :	0
Sub-Section Number :	1
Sub-Section Id :	3271872818
Question Shuffling Allowed :	No

Question Number : 1 Question Id : 32718729394 Question Type : SUBJECTIVE Consider As

Subjective : Yes

Correct Marks : 10

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. a) Explain the different types of fractionation regimens with clinical application of each. [4]
- b) Describe the mechanism of action of radiation sensitizers with an applied example. [3]
- c) Briefly describe the advantages of image guided adaptive brachytherapy over the traditional 2D film-based brachytherapy. [3]

Question Number : 2 Question Id : 32718729395 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Mechanism of action of taxane. [2]
- b) Describe various routes and dosing schedules for paclitaxel in gynecological cancers. [3]
- c) Describe common toxicities of taxane agents and how to prevent and treat them. [5]

Question Number : 3 Question Id : 32718729396 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Evidence for immunotherapy in cervical cancer. [4]
- b) How will you select a patient of cervical cancer for immunotherapy? [2]
- c) Role of anti-angiogenic agents in cervical cancer. [4]

Question Number : 4 Question Id : 32718729397 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Describe key clinical trials of maintenance PARP inhibitor therapy in ovarian cancer in primary setting. [5]
- b) Describe evidence for use of PARP inhibitor in the management of patient with BRCAwt/HRD positive with recurrent high grade serous ovarian cancer. [2]
- c) What are the common toxicities of PARPi and how to manage them? [3]

Question Number : 5 Question Id : 32718729398 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Describe role of palliative surgeries in the management of gynecological cancer patients. [7]
- b) What is end of life care? [3]

Question Number : 6 Question Id : 32718729399 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Phases of clinical trial. [2]
- b) What is a crossover trial design? Explain with an example. [4]
- c) Define case control study and cohort study. [4]

Question Number : 7 Question Id : 32718729400 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) P value and level of significance. [3]
- b) Types of errors and power of study. [4]
- c) Odds ratio and relative risk. [3]

Question Number : 8 Question Id : 32718729401 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Discuss the factors influencing the biological effect of a given dose of radiation. [3]
- b) Describe late toxicities of radiotherapy for cervical cancer and their management. [4]
- c) Discuss evidence for and advantages of IMRT in adjuvant setting. [3]

Question Number : 9 Question Id : 32718729402 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

Uterine sarcoma:

- a) Immunohistochemical (IHC) and molecular profiles of leiomyosarcoma and endometrial stromal sarcoma. [4]
- b) Indications for adjuvant chemotherapy and various chemotherapy protocols. [4]
- c) Role of hormonal therapy. [2]

Question Number : 10 Question Id : 32718729403 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) How socio-cultural factors may influence palliative care? [3]
- b) Benefits of Hospice care. [4]
- c) What are the various challenges faced by caregivers of gynecological cancer patients? [3]